Coherus BioSciences Proclaims New Employment Inducement Grants

0
6
Coherus BioSciences Announces New Employment Inducement Grants


REDWOOD CITY, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus” or the “Firm”, Nasdaq: CHRS), at present introduced that efficient November 19, 2020, the compensation committee of the Firm’s board of administrators granted choices to buy an mixture of 140,500 shares of the widespread inventory of the Firm to 10 newly employed non-officer workers, with a per share train value of $17.92, the closing buying and selling value on the grant date.

The inventory choices had been granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Graduation Incentive Plan, which was accepted by the Firm’s board of administrators in June 2016 underneath Rule 5635(c)(4) of the Nasdaq World Choose Marketplace for fairness grants to induce new workers to enter into employment with the Firm.

About Coherus BioSciences, Inc.

Coherus is a number one biosimilar firm that develops and commercializes its personal high-quality therapeutics in addition to these of others looking for succesful entry to the US market. Biosimilars are meant to be used instead of current, branded biologics to deal with a spread of power and infrequently life-threatening ailments, with the potential to cut back prices and increase affected person entry. Composed of a staff of confirmed trade veterans with world-class experience in course of science, analytical characterization, protein manufacturing, gross sales and advertising, clinical-regulatory growth and commercialization, Coherus is positioned as a pacesetter within the international biosimilar market. Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the US and is advancing extra product candidates together with CHS-1420, a Humira® (adalimumab) biosimilar, Bioeq’s Lucentis® (ranibizumab) biosimilar, Innovent’s Avastin® (bevacizumab) biosimilar in the direction of commercialization, in addition to CHS-2020, an Eylea® (aflibercept) biosimilar. For added info, please go to www.coherus.com.

Contact

David S. Arrington
Investor Relations & Company Affairs
Coherus BioSciences, Inc.
darrington@coherus.com
+1 (650) 395-0196



Supply hyperlink

This site uses Akismet to reduce spam. Learn how your comment data is processed.